WHAT IS CLAIMED IS:

1. A compound of the formula:




or a pharmaceutically acceptable salt thereof, wherein:

Ar is substituted phenyl, optionally substituted napthyl, or an optionally substituted heterocyclic group having from 1 to 3 rings, and 3 to 8 ring members in each ring and 1 to about 3 hetero atoms;

$R_1$ and $R_3$ are each independently hydrogen, halogen, cyano, nitro, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted mono or dialkylamino, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfinyl, or optionally substituted alkylsulfonyl; and

$R_2$ is halogen, cyano, nitro, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylamino, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfinyl, or optionally substituted alkylsulfonyl;

with the proviso that if Ar is phenyl substituted with halogen, napthyl, or naphthyl substituted with halogen, then the compounds where $R_3$ is hydrogen or amino are excluded.

2. A compound according to Claim 1, wherein:

Ar is substituted phenyl, optionally substituted naphthyl, or an optionally substituted heterocyclic group having at least one nitrogen ring atom or at least one sulfur ring atom.

3. A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

$R_1$ is selected from H, $C_{1-4}$ alkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, halogen, CN, $C_{1-4}$ haloalkyl, trifluoromethyl, trifluoromethoxy, -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), -O($C_{1-4}$ alkyl), and $S(O)_n$($C_{1-4}$ alkyl);

$R_2$ is selected from the group consisting of $-XR_A$ and Y, wherein –X, $R_A$, and Y are defined below; and

$R_3$ is selected from the group consisting of hydrogen, halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), and -$S(O)_n$($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, trifluoromethoxy, $-XR_A$ and Y;

$R_4$ is absent or an oxygen atom;

Ar is phenyl, mono-, di-, or tri-substituted with $R_C$, or

Ar is selected from the group consisting of:

naphthyl, pyridyl, pyridonyl, pyrimidinyl, and thiophenyl, each of which is unsubstituted or mono-, di-, or tri-substituted with $R_C$;

with the proviso that if Ar is phenyl substituted with halogen, napthyl, or naphthyl substituted with halogen, then the compounds where $R_3$ is hydrogen are excluded;

$R_A$ and $R_B$, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen and straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, each of which alkyl groups may contain one or more double or triple bonds, and may be further substituted with one or more substituent(s) selected from oxo, hydroxy, halogen, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), -NHC(O)($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)C(=O)($C_{1-4}$ alkyl), -$NHS(O)_n$($C_{1-4}$ alkyl), -$S(O)_n$($C_{1-4}$ alkyl), -$S(O)_n$NH($C_{1-4}$ alkyl), -$S(O)_n$N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), and Z;

$R_C$ is independently selected at each occurrence from the group consisting of halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl optionally substituted with 0-2 $R_D$, $C_{2-6}$ alkenyl substituted with 0-2 $R_D$, $C_{1-4}$ alkynyl substituted with

0-2 $R_D$, $C_{3-7}$ cycloalkyl substituted with 0-2 $R_D$, ($C_{3-7}$ cycloalkyl)$C_{1-4}$ alkyl substituted with 0-2 $R_D$, -O($C_{1-4}$ alkyl) substituted with 0-2 $R_D$, -NH($C_{1-4}$ alkyl) substituted with 0-2 $R_D$, -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl) each independently substituted with 0-2 $R_D$, -$XR_A$, and Y;

$R_D$ is independently selected at each occurrence the group consisting of halogen, hydroxy, cyano, $C_{1-4}$alkyl, -O($C_{1-4}$alkyl), -NH($C_{1-4}$alkyl), -N($C_{1-4}$alkyl)($C_{1-4}$alkyl), morpholino, pyrrolidino, piperidino, thiomorpholino, piperazino, 4-hydroxypiperidino, -$S(O)_n$($C_{1-4}$alkyl), trifluoromethyl, trifluoromethoxy, CO($C_{1-4}$alkyl), CONH($C_{1-4}$alkyl), CON($C_{1-4}$alkyl)($C_{1-4}$alkyl), -$XR_A$, and Y;

X is independently selected at each occurrence from the group consisting of -$CH_2$-, -$CHR_B$-, -O-, -C(=O)-, -C(=O)O-, -$S(O)_n$-, -NH-, -$NR_B$-, -C(=O)NH-, -C(=O)$NR_B$-, -$S(O)_n$NH-, -$S(O)_n$$NR_B$-, -OC(=S)S-, -NHC(=O)-, -$NR_B$C(=O)-, -$NHS(O)_n$-, -$OSiH_n$($C_{1-4}$alkyl)$_{2-n}$-, and –$NR_B$$S(O)_n$-; and

Y and Z are independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic and heterocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents selected from halogen, haloalkyl, oxo, hydroxy, amino, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), and -$S(O)_n$($C_{1-4}$ alkyl), and

said 3- to 7-membered heterocyclic groups contain one or more heteroatom(s) selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and

n is independently selected at each occurrence from 0, 1, and 2.

4. A compound of according to Claim 1 wherein Ar is substituted phenyl.

5. A compound according to Claim 3, wherein $R_4$ is absent and Ar is phenyl, mono-, di-, or tri-substituted with $R_C$.

6. A compound according to Claim 3 wherein $R_4$ is absent and Ar is phenyl, mono-, di-, or tri-substituted with $R_C$, and $R_1$ and $R_3$ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, ethoxy and methoxy.

7. A compound according to Claim 3 wherein $R_4$ is absent and Ar is phenyl, mono-, di-, or tri-substituted with $R_C$; and $R_A$ and $R_B$, which may be the same or different, are independently straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds.

8. A compound according to Claim 3 wherein $R_4$ is absent and Ar is phenyl mono-, di-, or tri-substituted with $R_C$; $R_A$ and $R_B$, which may be the same or different, are independently selected at each occurrence from the group consisting of: straight, branched, and cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds; and

$R_1$ and $R_3$ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, ethoxy, and methoxy.

9. A compound of the Formula:



Formula A

wherein

$R_X$ and $R_Y$ are the same or different and are independently selected straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds, each of which may be further substituted with one or more substituent(s) independently selected from hydroxy, halogen, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), : hydrogen and straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, each of which alkyl groups may contain one or more double or triple bonds, and may be further substituted with one or more substituent(s) selected from oxo, hydroxy, halogen, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), -NHC(O)($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)C(=O)($C_{1-4}$ alkyl), -NHS(O)$_n$($C_{1-4}$ alkyl), -S(O)$_n$($C_{1-4}$ alkyl), -

$S(O)_nNH(C_{1-4}$ alkyl), $-S(O)_nN(C_{1-4}$ alkyl)($C_{1-4}$ alkyl), Z, and phenyl, optionally mono-, di- or tri-substituted with substituents independently chosen from C1-4 alkoxy, C1-4 alkyl, halogen, CF3, OCF3, OCHF2, OH, and CN; and

Z is independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic and heterocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents selected from halogen, haloalkyl, oxo, hydroxy, amino, $C_{1-4}$ alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)($C_{1-4}$ alkyl), and $-S(O)_n(C_{1-4}$ alkyl), and

said 3- to 7-membered heterocyclic groups contain one or more heteroatom(s) selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and

n is independently selected at each occurrence from 0, 1, and 2.

10. A compound according to Claim 9, wherein Ar is phenyl, mono-, di-, or tri-substituted with $R_C$; and $R_1$ and $R_3$ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, ethoxy and methoxy.

11. A compound according to Claim 9, wherein:

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and

Ar is phenyl, which is mono-, di-, or trisubstituted with one or more substituent(s) independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

12. A compound according to Claim 9, wherein:

$R_X$ is hydrogen;

$R_Y$ is chosen from the group consisting of:

straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds;

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and

Ar is phenyl, which is mono-, di-, or trisubstituted with substituent(s) independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

13. A compound according to Claim 9, wherein:

$R_X$ is hydrogen;

$R_Y$ is chosen from the group consisting of:

straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds;

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and




is




and one, two or three of positions 2, 4, and 6 are substituted with substituent(s) independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

14. A compound according to Claim 9, wherein:

$R_X$ is hydrogen;

$R_Y$ is chosen from the group consisting of:

straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds;

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and




is




which is substituted at positions 2 and 4 with substituents independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

15. A compound according to Claim 9 of the formula:




wherein:

$R_1$ and $R_3$ are independently chosen at each occurrence from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and




is




and is substituted at positions 2 and 4 with substituents independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

16. A compound according to Claim 9 of the formula:




wherein

R is independently selected at each occurrence from the group consisting of: hydrogen, halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, $C_{1-6}$alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino; and

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy.

17. A compound according to Claim 9 wherein Ar is phenyl, which is mono-, di-, or tri-substituted with $R_C$;

$R_X$ and $R_Y$, which may be the same or different, are independently selected at each occurrence from the group consisting of: straight, branched, and cyclic alkyl groups having from 1 to 8 carbon atoms, which may contain one or more double or triple bonds; and

$R_1$ and $R_3$ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, ethoxy, and methoxy.

18. A compound according to Claim 3 of the formula:



wherein $R_X$ and $R_y$ are independently hydrogen or $C_{1\text{-}8}$ alkyl; or

$NR_XR_Y$ is:



wherein z is 0 or 1.

19. A compound of the Formula:



Formula B

wherein:

$R_X$ is chosen from the group consisting of:

straight, branched, or cyclic alkyl groups, including (cycloalkyl)alkyl groups, having from 1 to 8 carbon atoms, which groups may contain one or more double or triple bonds, each of which groups may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), -NHC(O)($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)C(=O)($C_{1-4}$ alkyl), -NHS(O)$_n$($C_{1-4}$ alkyl), -S(O)$_n$($C_{1-4}$ alkyl), -S(O)$_n$NH($C_{1-4}$ alkyl), -S(O)$_n$N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), Z, and phenyl, optionally mono-, di- or tri-substituted with substituents independently chosen from C1-4 alkoxy, C1-4 alkyl, halogen, CF3, OCF3, OCHF2, OH, and CN; and

Z is independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic and heterocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents selected from halogen, haloalkyl, oxo, hydroxy, amino, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), and -S(O)$_n$($C_{1-4}$ alkyl), and

said 3- to 7-membered heterocyclic groups contain one or more heteroatom(s) selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and

n is independently selected at each occurrence from 0, 1, and 2.

20. A compound according to Claim 19, wherein:

$R_x$ is selected from straight, branched, or cyclic alkyl groups containing of 1 to 8 carbon atoms, which may contain one or more double or triple bonds;

and;

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and

Ar is phenyl, which is mono-, di-, or trisubstituted with one or more substituent(s) independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

21. A compound according to Claim 20, wherein:




is




and is substituted at substituted at one, two, or three of positions 2, 4, and 6 with substituent(s)independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, and $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

22. A compound according to Claim 20, wherein:




is




and is substituted at positions 2 and 4 with substituents independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

23. A compound according to Claim 19, of the formula:



wherein:

$R_1$ and $R_3$ are independently chosen from halogen, $C_{1-4}$ alkyl, -O($C_{1-4}$ alkyl), -NH($C_{1-4}$ alkyl), -N($C_{1-4}$ alkyl)($C_{1-4}$ alkyl), haloalkyl, trifluoromethyl, and trifluoromethoxy; and



is



and is substituted at substituted at one, two, or three of positions 2, 4, and 6 with substituent(s)independently selected from:

halogen, cyano, haloalkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, $C_{1-6}$ alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy($C_{1-4}$alkoxy), mono- or di($C_{1-4}$)amino($C_{1-4}$alkoxy), and mono- or di($C_{1-4}$ alkyl)amino.

24. A compound according to Claim 19 wherein $R_1$ and $R_3$ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, ethoxy and methoxy.

25. A compound according to Claim 3 of the formula:



wherein A is $NR_A$ or O.

26. A compound according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 1 micromolar.

27. A method for modulating CRF receptor function, comprising administering to a patient in need of such modulation an effective amount of a compound of according to Claim 1.

28. A method for treating a CNS disorder or disease, comprising administering to a patient in need of such treatment an effective amount of a compound according to Claim 1.

29. The method of Claim 28 wherein the CNS disorder or disease is an anxiety disorder, stress-related disorder, or eating disorder.

30. A compound according to Claim 1, wherein in a standard in vitro sodium channel functional assay the compound does not show any statistically significant activity at the $p < 0.05$ level of significance.

31. A method of Claim 28 wherein the CNS disease or disorder is depression or a bipolar disorder.

32. A method of Claim 28 wherein the CNS disease or disorder is anorexia nervosa, bulimia nervosa, or obesity.

33. A method according to Claim 28 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 1 micromolar.

34. A method according to Claim 28 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 100 nanomolar.

35. A method according to Claim 28 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 10 nanomolar.

36. A method according to Claim 28 wherein the patient is a human.

37. A method for localizing CRF receptors is tissue section samples comprising:

contacting with a sample of tissue a deteactably-labelled compound of Claim 1 under conditions that permit binding of the compound to CRF receptors within the sample of tissue;

washing the tissue sample to remove unbound compound; and

detecting remaining bound compound.

38. A method of inhibiting the binding of CRF to a CRF1 Receptor which comprises:

contacting a solution comprising CRF and a compound of Claim 3 with a cell the receptor, wherein the compound is present in the solution at a concentration sufficient to inhibit CRF binding to IMR32 cells in vitro.

39. A method for altering the signal-transducing activity of a CRF1 receptor, the method comprising contacting cells expressing the receptor with a compound according to Claim 3.

40. A method of modulating G-protein coupled receptor function, the method comprising exposing cells expressing a G-protein coupled receptor to an effective amount of a compound according to Claim 3.

41. A method according to Claim 40, wherein the G-coupled protein receptor is a CRF1 receptor.

42. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of a compound according to Claim 1.

43. A packaged pharmaceutical composition comprising a pharmaceutical composition of claim 42 in a container and instructions for using the composition to treat a patient suffering from an anxiety disorder, a stress-related disorder, or an eating disorder.

44. A compound according to Claim 3, named 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

45. A compound according to Claim 3, named 5-[4-bromo-2-(trifluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine.

46. A compound according to Claim 3, named 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl] pyrazin-2-amine.

47. A compound according to Claim 3, named 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

48. A compound according to Claim 3, named 5-[2-chloro-4-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

49. A compound according to Claim 3, named 2-[2,4-bis(trifluoromethyl)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

50. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-naphthyl)pyrazin-2-amine.

51. A compound according to Claim 3, named 5-[4-chloro-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine.

52. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-[2-

methoxy-6-(trifluoromethoxy)phenyl]pyrazin-2-amine.

53. A compound according to Claim 3, named 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

54. A compound according to Claim 3, named 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine.

55. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl-1,1'-biphenyl-4-yl)pyrazin-2-amine.

56. A compound according to Claim 3, named 5-[2,4-bis(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

57. A compound according to Claim 3, named 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1-methylbutoxy)pyrazine.

58. A compound according to Claim 3, named 2,5-diethyl-3-(1-isopropyl-2-methylpropoxy)-6-[4-methoxy-2-(trifluoromethoxy)phenyl]pyrazine.

59. A compound according to Claim 3, named 2,5-diethyl-3-(1-isopropyl-2-methylpropoxy)-6-[2-methyl-4-(trifluoromethoxy)phenyl]pyrazine.

60. A compound according to Claim 3, named 5-[4-chloro-2-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

61. A compound according to Claim 3, named N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazin-2-amine.

62. A compound according to Claim 3, named 5-[4-chloro-2-

(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

63. A compound according to Claim 3, named 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methyl-4-(trifluoromethoxy)phenyl]pyrazin-2-amine.

64. A compound according to Claim 3, named 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

65. A compound according to Claim 3, named 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

66. A compound according to Claim 3, named O-(3-chloro-4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}phenyl) S-propyl (dithiocarbonate).

67. A compound according to Claim 3, named 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]pyrazine.

68. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)pyrazin-2-amine.

69. A compound according to Claim 3, named 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine.

70. A compound according to Claim 3, named 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine.

71. A compound according to Claim 3, named O-(3-chloro-4-{3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazin-2-yl}phenyl) S-propyl (dithiocarbonate).

72. A compound according to Claim 3, named 5-(4-chloro-2,6-dimethoxyphenyl)-N-

(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

73. A compound according to Claim 3, named 2-(2,4-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylbutoxy)pyrazine.

74. A compound according to Claim 3, named 5-[4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

75. A compound according to Claim 3, named 5-(4-ethoxy-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

76. A compound according to Claim 3, named 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-6-methylphenyl)pyrazin-2-amine.

77. A compound according to Claim 3, named 2-(2-chloro-4-methoxyphenyl)-3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazine.

78. A compound according to Claim 3, named 2-(4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxyphenyl)propan-2-ol.

79. A compound according to Claim 3, named 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

80. A compound according to Claim 3, named 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

81. A compound according to Claim 3, named 5-(4-chloro-2-ethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

82. A compound according to Claim 3, named 5-(2-chloro-4-isopropoxyphenyl)-3-

ethyl-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

83. A compound according to Claim 3, named 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine.

84. A compound according to Claim 3, named 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

85. A compound according to Claim 3, named 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methylpyrazin-2-amine.

86. A compound according to Claim 3, named 5-[2'-chloro-4',5-bis(trifluoromethyl)-1,1'-biphenyl-2-yl]-N-(1-ethylpropyl)-6-methoxy-3-methylpyrazin-2-amine.

87. A compound according to Claim 3, named N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-methylpyrazin-2-amine.

88. A compound according to Claim 3, named 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methylpyrazin-2-amine.

89. A compound according to Claim 3, named 2,5-diethyl-3-(2-ethyl-4-methoxyphenyl)-6-(1-isopropyl-2-methylpropoxy)pyrazine.

90. A compound according to Claim 3, named 5-(4-ethoxy-2-isopropoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

91. A compound according to Claim 3, named 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

92. A compound according to Claim 3, named 2-[2-chloro-4-

(trifluoromethyl)phenyl]-3,6-diethyl-5-(1-ethylbutoxy)pyrazine.

93. A compound according to Claim 3, named N-(1-ethylpropyl)-5-[4-(1-fluoroethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methylpyrazin-2-amine.

94. A compound according to Claim 3, named 5-[2-chloro-4-(2-methoxyethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

95. A compound according to Claim 3, named 5-[4-(difluoromethoxy)-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

96. A compound according to Claim 3, named 5-{2-[(dimethylamino)methyl]-4-methoxyphenyl}-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine.

97. A compound according to Claim 3, named (2-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-5-methoxyphenyl)methanol.

98. A compound according to Claim 3, named 5-[4-(difluoromethoxy)-2-methoxyphenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxypyrazin-2-amine.

99. A compound according to Claim 3, named 2-(2-chloro-4-propoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

100. A compound according to Claim 3, named 2-[2-chloro-4-(cyclopropylmethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

101. A compound according to Claim 3, named 2-[2-chloro-4-(2-fluoroethoxy)phenyl]-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

102. A compound according to Claim 3, named N-(1-ethylpropyl)-5-(4-isopropoxy-2-

methoxyphenyl)-3-methoxy-6-methylpyrazin-2-amine.

103. A compound according to Claim 3, named 2-(4-{[tert-butyl(dimethyl)silyl]oxy}-2-isopropoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

104. A compound according to Claim 3, named 2-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

105. A compound according to Claim 3, named 2-(2,6-dimethoxyphenyl)-3,6-diethyl-5-(1-ethylbutoxy)pyrazine.

106. A compound according to Claim 3, named 4-{3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazin-2-yl}-3-methoxyphenol.

107. A compound according to Claim 3, named 6-ethyl-N-(1-ethylpropyl)-5-(4-isopropoxy-2-methoxyphenyl)-3-methoxypyrazin-2-amine.

108. A compound according to Claim 3, named 4-[3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazin-2-yl]-3-ethylphenol.

109. A compound according to Claim 3, named 3-ethyl-N-(1-ethylpropyl)-5-[4-fluoro-2-(trifluoromethyl)phenyl]-6-methoxypyrazin-2-amine.

110. A compound according to Claim 3, named 2,5-diethyl-3-(1-isopropyl-2-methylpropoxy)-6-mesitylpyrazine.

111. A compound according to Claim 3, named 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-methoxy-2-methylphenyl)pyrazine.

112. A compound according to Claim 3, named 2,5-diethyl-3-[4-methoxy-2-

(trifluoromethoxy)phenyl]-6-(1-propylbutoxy)pyrazine.

113. A compound according to Claim 3, named 6-chloro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazin-2-amine.

114. A compound according to Claim 3, named 2-(4-butoxy-2-chlorophenyl)-3,6-diethyl-5-(1-ethylbutoxy)pyrazine.

115. A compound according to Claim 3, named 3-bromo-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazin-2-amine.

116. A compound according to Claim 3, named 2-(4-{[tert-butyl(dimethyl)silyl]oxy}-2-ethoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine.

117. A compound according to Claim 3, named 6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazin-2-ylformamide.

118. A compound according to Claim 3, named 2,5-diethyl-3-(2-ethylbutyl)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazine.

119. A compound according to Claim 3, named 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-isopropoxy-4-propoxyphenyl)pyrazine.

120. A compound according to Claim 3, named 2-(sec-butylthio)-5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazine.

121. A compound according to Claim 3, named 5-(4-chloro-2,6-dimethoxyphenyl)-6-methoxypyrazin-2-amine.

122. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methyl-4-chlorophenyl)pyrazin-2-amine.

123. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methyl-4-fluorophenyl)pyrazin-2-amine.

124. A compound according to Claim 3, named 3,6-diethyl-N,N-(2-methoxyethyl)-5-(2,4-dichlorophenyl)pyrazin-2-amine.

125. A compound according to Claim 3, named 3,6-diethyl-N-propyl-N-(cyclopropylmethyl)-5-(2,4-dichlorophenyl)pyrazin-2-amine.

126. A compound according to Claim 3, named 3,6-diethyl-2-(1-ethylpropoxy)-5-(2-methoxy-4,6-dimethylphenyl)pyrazine.

127. A compound according to Claim 3, named 3,6-dimethyl-2-(1-ethylpropoxy)-5-(2,4-dichlorophenyl)pyrazine.

128. A compound according to Claim 3, named 3,6-diethyl-2-(1-ethylpropoxy)-5-(2-hydroxy-4,6-dimethylphenyl)pyrazine.

129. A compound according to Claim 3, named 3,6-diethyl-2-(1-ethylpropoxy)-5-(2,4-dichlorophenyl)pyrazine.

130. A compound according to Claim 3, named 3,6-dimethyl-N-(1-methoxy-2-butyl)-5-(2,4-dimethoxyphenyl) pyrazin-2-amine.

131. A compound according to Claim 3, named 2-(2,4-dichlorophenyl)-5-[2-(methoxymethyl)pyrrolidin-1-yl]-3,6-dimethylpyrazine.

132. A compound according to Claim 3, named 2-(2,4-dimethoxyphenyl)-5-[2-(methoxymethyl) pyrrolidin-1-yl]-3,6-dimethylpyrazine.

133. A compound according to Claim 3, named 3,6-dimethyl-N-(1-ethylpropyl)-5-(2-methyl-4-chlorophenyl)pyrazin-2-amine.

134. A compound according to Claim 3, named 3,6-dimethyl-N-(1-ethylpropyl)-5-(2-trifluoromethyl-4-dimethylaminophenyl)pyrazin-2-amine.

135. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-trifluoromethoxy-4-methoxyphenyl)pyrazin-2-amine.

136. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-trifluoromethylphenyl)pyrazin-2-amine.

137. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-trifluoromethyl-4-methoxyphenyl)pyrazin-2-amine.

138. A compound according to Claim 3, named 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)pyrazin-2-amine.

139. A compound according to Claim 3, named 3,6-diethyl-N-(1-methoxy-2-butyl)-5-(2-chloro-4-dimethylaminophenyl)pyrazin-2-amine.

140. A compound according to Claim 3, named 3,6-diethyl-N-(1-methylpropyl)-5-(2-chloro-4-dimethylaminophenyl)pyrazin-2-amine.

141. A compound according to Claim 3, named 3,6-diethyl-N-(2-methylpropyl)-5-(2-chloro-4-dimethylaminophenyl)pyrazin-2-amine.

142. A compound according to Claim 3, named 3,6-diethyl-N-(2-phenylethyl)-5-(2-chloro-4-dimethylphenyl)pyrazin-2-amine.

143. A compound according to Claim 3, named 3,6-diethyl-N-(1-propylbutyl)-5-(2-trifluoromethyl-4-dimethylaminophenyl) pyrazin-2-amine.

144. A compound according to Claim 3, named 3,6-diethyl-N-(1-methoxy-2-butyl)-5-(2-trifluoromethyl-4-dimethylaminophenyl) pyrazin-2-amine.

145. A compound according to Claim 3, named 2-(2,6-dimethoxy-4-chloro-phenyl)-6-ethyl-5-(1-ethylpropoxy)-3-methoxypyrazine.

146. A compound named 2-(2-methoxy-5-triflurormethoxyphenyl)-3-ethyl-6-methylamino-5-(1-ethylpropoxy)-pyrazine.

147. A method for treating a CNS disorder or disease, comprising administering to a patient in need of such treatment between 0.1 to 140 mg per kg body weight per day of a compound according to Claim 3.

148. The method of Claim 147 wherein the CNS disorder or disease is an anxiety disorder, stress-related disorder, or eating disorder.

149. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of a compound according to Claim 3.

150. A compound according to Claim 3 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 1 micromolar.

151. A method for modulating CRF receptor function, comprising administering to a patient in need of such modulation an effective amount of a compound of according to Claim 3.

152. A method for treating a CNS disorder or disease, comprising administering to a patient in need of such treatment an effective amount of a compound according to Claim 3.

153. The method of Claim 152 wherein the CNS disorder or disease is an anxiety disorder, stress-related disorder, or eating disorder.

154. A compound according to Claim 3, wherein in a standard in vitro sodium channel functional assay the compound does not show any statistically significant activity at the $p < 0.05$ level of significance.

155. A method of Claim 152 wherein the CNS disease or disorder is depression or a bipolar disorder.

156. A method of Claim 152 wherein the CNS disease or disorder is anorexia nervosa, bulimia nervosa, or obesity.

157. A method according to Claim 152 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 1 micromolar.

158. A method according to Claim 152 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 100 nanomolar.

159. A method according to Claim 152 wherein in a standard in vitro CRF receptor binding assay the compound exhibits an $IC_{50}$ value less than or equal to 10 nanomolar.

160. A method according to Claim 152 wherein the patient is a human.

161. A method for localizing CRF receptors is tissue section samples comprising:

contacting with a sample of tissue a deteactably-labelled compound of Claim 3 under conditions that permit binding of the compound to CRF receptors within the sample of tissue;

washing the tissue sample to remove unbound compound; and

detecting remaining bound compound.

162. A packaged pharmaceutical composition comprising a pharmaceutical composition of claim 149 in a container and instructions for using the composition to treat a patient suffering from an anxiety disorder, a stress-related disorder, or an eating disorder.